# Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
Canonical URL: https://biopharmsignal.com/news/BTMD/biote-appoints-komal-bajaj-md-ms-as-chief-medical-officer
Ticker: BTMD
Company: biote Corp
Source: biote Corp
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.biote.com
## Summary

IRVING, Texas --(BUSINESS WIRE)--Jun. 1, 2026-- Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and

## Article Body
IRVING, Texas --(BUSINESS WIRE)--Jun. 1, 2026-- Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj is a nationally recognized physician executive, board-certified OB/GYN and
## Recent Company News
- 2026-06-25 13:46 EST — [Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer](https://biopharmsignal.com/news/BTMD/biote-appoints-komal-bajaj-md-ms-as-chief-medical-officer) — Source: biote Corp
- 2026-06-25 13:46 EST — [Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO](https://biopharmsignal.com/news/BTMD/biote-names-bob-peterson-current-chief-financial-and-chief-business-officer-as-interim-ceo) — Source: biote Corp
- 2026-06-25 13:46 EST — [Biote Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/BTMD/biote-reports-first-quarter-2026-financial-results) — Source: biote Corp
- 2026-06-25 13:46 EST — [Biote Reports First Quarter 2025 Financial Results](https://biopharmsignal.com/news/BTMD/biote-reports-first-quarter-2025-financial-results) — Source: biote Corp
- 2026-06-25 13:46 EST — [Biote Names Rich Barrera to Board of Directors](https://biopharmsignal.com/news/BTMD/biote-names-rich-barrera-to-board-of-directors) — Source: biote Corp
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)